Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports.

European journal of gynaecological oncology - 1 Jan 2008

Melichar B, Fridrichová P, Lukesová S, Mergancová J, Urminská H, Ryska A, Foretová L

Abstract excerpt

The prognosis of patients with BRCA1-related breast carcinomas is inferior to the patients without BRCA1 mutation, but most of these tumors have a so-called triple negative phenotype characterized by increased chemosensitivity. Information regarding the chemosensitivity of BRCA1-related breast ca...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Mothers

Share to Nuclear Family

Share to Paclitaxel

Share to Ubiquitin-Protein Ligases

Source

Identifiers

PMID: 18459563

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18459563-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports.PMID 18459563Read ↗

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.Semantic proximity Read ↗

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Semantic proximity Read ↗

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.Semantic proximity Read ↗

Sensitivity of BRCA-1-related breast cancer to neoadjuvant chemotherapy: practical implications.Semantic proximity Read ↗

Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report.Semantic proximity Read ↗

Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible CombinationSemantic proximity Read ↗

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Semantic proximity Read ↗

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.